FATE THERAPEUTICS INC Deferred Tax Liabilities, Gross
FATE THERAPEUTICS INC (FATE) had Deferred Tax Liabilities, Gross of $11.36 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Gross $11.36M.
- 2024-12-31: Deferred Tax Liabilities, Gross $12.01M.
- 2023-12-31: Deferred Tax Liabilities, Gross $18.67M.
- 2022-12-31: Deferred Tax Liabilities, Gross $20.69M.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $11.36M 10-K · filed 2026-02-26 |
| 2024-12-31 | $12.01M 10-K · filed 2026-02-26 |
| 2023-12-31 | $18.67M 10-K · filed 2025-03-05 |
| 2022-12-31 | $20.69M 10-K · filed 2024-02-26 |
| 2021-12-31 | $22.17M 10-K · filed 2023-02-28 |
| 2020-12-31 | $18.31M 10-K · filed 2022-02-28 |
| 2019-12-31 | $4.78M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |